Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Ask a Question
PubMed This is a summary of 16 peer-reviewed journal articles Updated
Endocrinology

The Biology and Diagnosis of AGL

At a Glance

AGL is usually an autoimmune condition where the immune system mistakenly attacks fat cells, causing widespread fat loss. This destruction makes leptin hormone levels drop near zero, resulting in extreme hunger and metabolic issues. Doctors confirm AGL using specific blood tests for anti-PLIN1 antibodies.

Understanding the “why” behind Acquired Generalized Lipodystrophy (AGL) requires looking at the specialized biology of fat cells. Fat cells (adipocytes) are not just storage containers; they are active chemical factories that produce essential hormones [1]. In AGL, this factory system is systematically shut down or destroyed by your own body [2].

The Immune System Mistake

The most common cause of AGL is a breakdown in “immune tolerance.” Normally, your immune system protects you from outside threats like viruses. In AGL, the immune system mistakenly identifies a protein called perilipin 1 (PLIN1) as a threat [3].

PLIN1 is like a “security guard” for the fat droplets inside your cells, helping to regulate how fat is stored and released. When your body creates anti-PLIN1 autoantibodies, they attack this security guard [2]. This attack leads to:

  • Leakage: Fat is forced out of the storage cells prematurely (increased lipolysis) [2][4].
  • Destruction: The fat cells themselves eventually die off, leaving no place for your body to store energy [4].

Subtypes of AGL

Doctors categorize AGL based on what may have triggered the immune system’s confusion:

  • Autoimmune (Lawrence Syndrome): This is often associated with other autoimmune diseases like Hashimoto’s thyroiditis or autoimmune hepatitis [3][5].
  • Panniculitis-Associated: In this type, the fat loss is preceded by painful, inflamed nodules under the skin (panniculitis) [6][7].
  • ICI-Induced: A newer subtype caused by certain cancer treatments called immune checkpoint inhibitors (e.g., pembrolizumab). These drugs “unleash” the immune system to fight cancer, but in rare cases, the immune system also attacks the patient’s fat cells [8][9].
  • Idiopathic: This term is used when the fat loss occurs without a clear inflammatory or autoimmune trigger [4].

The Role of Leptin

The most critical hormone produced by your fat is leptin. Leptin is your body’s “satiety signal”—it tells your brain how much energy you have in storage [10]. When fat cells disappear in AGL, leptin production drops to nearly zero [11]. Without leptin:

  1. Your brain thinks you are starving: This leads to hyperphagia, an intense and unrelenting hunger [12].
  2. Your metabolism breaks down: Without leptin to help manage insulin, sugar stays in your blood, and fat begins to build up in your liver and muscles [10][13].

How Doctors Confirm AGL

Because AGL is so rare, it can sometimes be confused with other conditions. Doctors use specific markers to tell them apart:

Feature Acquired Generalized Lipodystrophy (AGL) Anorexia Nervosa Congenital Generalized Lipodystrophy (CGL)
Onset Later in life (childhood/adulthood) [14]. Typically adolescence [11]. Present at birth [15].
Leptin Levels Extremely Low (near zero) [11]. Low, but comparable to a thin person [11]. Extremely Low [11].
Genetic Cause Usually No (Autoimmune) [3]. No. Yes (Genetic mutations like AGPAT2) [16].
Adiponectin Very Low HMW Adiponectin [11]. Normal or High HMW Adiponectin [11]. Very Low [11].

Confirming the presence of anti-PLIN1 autoantibodies or seeing the hallmark low leptin levels helps your care team ensure they are treating the correct underlying biological problem [3][11]. Note that the anti-PLIN1 test is highly specialized; your local clinic will likely need to send your blood sample to a specialized immunology or academic research laboratory.

Common questions in this guide

What causes Acquired Generalized Lipodystrophy (AGL)?
AGL is most commonly caused by an autoimmune reaction where the body mistakenly attacks its own fat cells. The immune system targets a protein called perilipin 1 (PLIN1), which forces fat out of storage cells and eventually destroys them.
How is AGL diagnosed differently from anorexia nervosa?
While both conditions involve severe weight loss, they look very different in blood tests. People with AGL have near-zero levels of the hormone leptin and very low adiponectin. In anorexia nervosa, these hormone levels are typically normal or similar to those of a naturally thin person.
Can cancer treatments cause Acquired Generalized Lipodystrophy?
Yes, a newer subtype of AGL can be triggered by immune checkpoint inhibitors, which are medications used to treat certain cancers. In rare cases, these drugs can cause the immune system to mistakenly attack fat cells in addition to cancer cells.
What is the anti-PLIN1 test for AGL?
The anti-PLIN1 test checks your blood for specific autoantibodies that attack the perilipin 1 protein in your fat cells. A positive result helps your medical team confirm that an autoimmune problem is the underlying cause of your generalized fat loss.
Why do people with AGL feel extremely hungry all the time?
Fat cells normally produce a hormone called leptin, which tells your brain that you have enough stored energy. Because AGL destroys fat cells, leptin levels drop drastically, tricking the brain into thinking it is starving and causing intense, unrelenting hunger.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Should I be tested for anti-perilipin 1 (PLIN1) autoantibodies to see if my AGL is autoimmune-related?
  2. 2.How do my serum leptin and HMW adiponectin levels compare to those of a person with typical weight loss or anorexia?
  3. 3.Could my recent medications, specifically immune checkpoint inhibitors, have triggered this fat loss?
  4. 4.What is the plan for monitoring my liver health and screening for potential paraneoplastic triggers?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (16)
  1. 1

    Advanced Lipoprotein Analysis Shows Atherogenic Lipid Profile That Improves After Metreleptin in Patients with Lipodystrophy.

    Kinzer AB, Shamburek RD, Lightbourne M, et al.

    Journal of the Endocrine Society 2019; (3(8)):1503-1517 doi:10.1210/js.2019-00103.

    PMID: 31620670
  2. 2

    Characterization and Clinical Association of Autoantibodies Against Perilipin 1 in Patients With Acquired Generalized Lipodystrophy.

    Corvillo F, Abel BS, López-Lera A, et al.

    Diabetes 2023; (72(1)):71-84 doi:10.2337/db21-1086.

    PMID: 35771980
  3. 3

    Autoantibodies to Perilipin-1 Define a Subset of Acquired Generalized Lipodystrophy.

    Mandel-Brehm C, Vazquez SE, Liverman C, et al.

    Diabetes 2023; (72(1)):59-70 doi:10.2337/db21-1172.

    PMID: 35709010
  4. 4

    Autoantibodies Against Perilipin 1 as a Cause of Acquired Generalized Lipodystrophy.

    Corvillo F, Aparicio V, López-Lera A, et al.

    Frontiers in immunology 2018; (9()):2142 doi:10.3389/fimmu.2018.02142.

    PMID: 30283460
  5. 5

    Clinical Characterisation and Comorbidities of Acquired Generalised Lipodystrophy: A 14-Year Follow-Up Study.

    Fernandez-Pombo A, Prado-Moraña T, Diaz-Lopez EJ, et al.

    Journal of clinical medicine 2023; (12(23)) doi:10.3390/jcm12237344.

    PMID: 38068396
  6. 6

    An unusual case of acquired generalized lipodystrophy (panniculitis variety).

    Hill M, Weissman AS, Hirshburg J, et al.

    Pediatric dermatology 2024; (41(6)):1152-1155 doi:10.1111/pde.15668.

    PMID: 38887123
  7. 7

    Corticosteroid-triggered acute skeletal muscle loss in lipodystrophy: A case report.

    Sasako T, Suzuki K, Odawara S, et al.

    Journal of diabetes investigation 2024; (15(6)):782-785 doi:10.1111/jdi.14158.

    PMID: 38372649
  8. 8

    Acquired Generalized Lipodystrophy: A New Cause of Anti-PD-1 Immune-Related Diabetes.

    Jehl A, Cugnet-Anceau C, Vigouroux C, et al.

    Diabetes care 2019; (42(10)):2008-2010 doi:10.2337/dc18-2535.

    PMID: 31434650
  9. 9

    A CASE OF ACQUIRED GENERALIZED LIPODYSTROPHY ASSOCIATED WITH PEMBROLIZUMAB IN A PATIENT WITH METASTATIC MALIGNANT MELANOMA.

    Bedrose S, Turin CG, Lavis VR, et al.

    AACE clinical case reports 2020; (6(1)):e40-e45 doi:10.4158/ACCR-2019-0234.

    PMID: 32524008
  10. 10

    Eating behaviour in contrasting adiposity phenotypes: Monogenic obesity and congenital generalized lipodystrophy.

    Santos JL, Cortés VA

    Obesity reviews : an official journal of the International Association for the Study of Obesity 2021; (22(1)):e13114 doi:10.1111/obr.13114.

    PMID: 33030294
  11. 11

    Serum levels of adiponectin differentiate generalized lipodystrophies from anorexia nervosa.

    Ceccarini G, Pelosini C, Paoli M, et al.

    Journal of endocrinological investigation 2024; (47(8)):1881-1886 doi:10.1007/s40618-024-02308-3.

    PMID: 38358463
  12. 12

    Metreleptin-mediated improvements in insulin sensitivity are independent of food intake in humans with lipodystrophy.

    Brown RJ, Valencia A, Startzell M, et al.

    The Journal of clinical investigation 2018; (128(8)):3504-3516.

    PMID: 29723161
  13. 13

    Complications of lipodystrophy syndromes.

    Akinci G, Celik M, Akinci B

    Presse medicale (Paris, France : 1983) 2021; (50(3)):104085 doi:10.1016/j.lpm.2021.104085.

    PMID: 34728268
  14. 14

    Generalized lipoatrophy syndromes.

    Sorkina E, Chichkova V

    Presse medicale (Paris, France : 1983) 2021; (50(3)):104075 doi:10.1016/j.lpm.2021.104075.

    PMID: 34562560
  15. 15

    [Unusual facies and recurrent high triglycerides for more than one year in a girl].

    Yin ZX, He XL, Zou RY

    Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics 2018; (20(12)):1050-1054.

    PMID: 30572997
  16. 16

    Expression of AGPAT2, an enzyme involved in the glycerophospholipid/triacylglycerol biosynthesis pathway, is directly regulated by HIF-1 and promotes survival and etoposide resistance of cancer cells under hypoxia.

    Triantafyllou EA, Georgatsou E, Mylonis I, et al.

    Biochimica et biophysica acta. Molecular and cell biology of lipids 2018; (1863(9)):1142-1152 doi:10.1016/j.bbalip.2018.06.015.

    PMID: 29908837

This page explains the biology and diagnosis of Acquired Generalized Lipodystrophy for educational purposes only. Always consult a qualified endocrinologist or immunologist to interpret your specific laboratory results and symptoms.

Get notified when new evidence is published on Acquired generalized lipodystrophy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.